Solid Biosciences Stock Forecast, Price & News

+0.12 (+3.05 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume668,154 shs
Average Volume1.38 million shs
Market Capitalization$447.81 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Solid Biosciences logo

About Solid Biosciences

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.99 out of 5 stars

Medical Sector

92nd out of 2,100 stocks

Biological Products, Except Diagnostic Industry

13th out of 198 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

Is Solid Biosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Solid Biosciences stock.
View analyst ratings for Solid Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Solid Biosciences?

Wall Street analysts have given Solid Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Solid Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Solid Biosciences

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc. (NASDAQ:SLDB) released its quarterly earnings data on Thursday, May, 13th. The company reported ($0.19) EPS for the quarter, beating the Zacks' consensus estimate of ($0.32) by $0.13.
View Solid Biosciences' earnings history

How has Solid Biosciences' stock been impacted by Coronavirus (COVID-19)?

Solid Biosciences' stock was trading at $3.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SLDB stock has increased by 29.3% and is now trading at $4.06.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SLDB?

5 analysts have issued 12 month target prices for Solid Biosciences' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Solid Biosciences' share price to reach $11.60 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price.
View analysts' price targets for Solid Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the following people:
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 47, Pay $829.25k)
  • Mr. Matthew Bennett Arnold, Co-Founder & Independent Director (Age 51, Pay $42.5k)
  • Dr. Carl Ashley Morris, Chief Scientific Officer (Age 51, Pay $547.4k)
  • Ms. Annie Ganot, Co-Founder & Director of Patient Advocacy
  • Mr. Stephen J. DiPalma M.B.A., Interim CFO, Treasurer & Principal Accounting Officer (Age 62)
  • Dr. Joel Solomon Zev Schneider, Chief Operating Officer (Age 36)
  • Mr. Geoffrey M. Grande, VP & Head of Investor Relations
  • Ms. Erin Powers Brennan, Chief Legal Officer & Sec. (Age 50)
  • Mr. Tim Palmer, Corp. Communications Mang.
  • Dr. Cathryn M. Clary M.B.A., M.D., Acting Chief Medical Officer

Who are some of Solid Biosciences' key competitors?

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Cidara Therapeutics (CDTX), SCYNEXIS (SCYX), Verastem (VSTM) and Agile Therapeutics (AGRX).

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (12.16%), RA Capital Management L.P. (11.21%), EcoR1 Capital LLC (8.34%), Suvretta Capital Management LLC (5.42%), Price T Rowe Associates Inc. MD (3.82%) and BlackRock Inc. (2.24%). Company insiders that own Solid Biosciences stock include Carl Ashley Morris, Ilan Ganot, Jennifer Lynn Ziolkowski, Joel Solomon Zev Schneider, Life Sciences Maste Perceptive, Perceptive Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends for Solid Biosciences

Which institutional investors are selling Solid Biosciences stock?

SLDB stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, D. E. Shaw & Co. Inc., JPMorgan Chase & Co., Morgan Stanley, Northern Trust Corp, Russell Investments Group Ltd., Bank of New York Mellon Corp, and The Manufacturers Life Insurance Company. Company insiders that have sold Solid Biosciences company stock in the last year include Carl Ashley Morris, Ilan Ganot, Jennifer Lynn Ziolkowski, and Joel Solomon Zev Schneider.
View insider buying and selling activity for Solid Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Solid Biosciences stock?

SLDB stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Perceptive Advisors LLC, RA Capital Management L.P., Suvretta Capital Management LLC, EcoR1 Capital LLC, Nuveen Asset Management LLC, Barclays PLC, and Alyeska Investment Group L.P.. Company insiders that have bought Solid Biosciences stock in the last two years include Life Sciences Maste Perceptive, Perceptive Advisors Llc, and Ra Capital Management, LP.
View insider buying and selling activity for Solid Biosciences
or or view top insider-buying stocks.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $4.06.

How much money does Solid Biosciences make?

Solid Biosciences has a market capitalization of $447.81 million. The company earns $-88,290,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

How many employees does Solid Biosciences have?

Solid Biosciences employs 70 workers across the globe.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is

Where are Solid Biosciences' headquarters?

Solid Biosciences is headquartered at 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.